NCT06716021 - ReVeRA-301: Etripamil in Atrial Fibrillation Phase 3 | Biotech Hunter

Enrollment

750

Participants

Timeline

Start Date

January 31, 2026

Primary Completion Date

January 31, 2028

Study Completion Date

January 31, 2029

Conditions

Atrial Fibrillation

Interventions

DRUG

Placebo

The formulation of placebo will consist of water, sodium acetate, disodium EDTA, and sulfuric acid to reproduce the same pH as the etripamil formulation.

DRUG

Etripamil

The formulation of etripamil is for IN administration and will consist of etripamil, water, acetic acid, disodium ethylene-diamine-tetra-acetic acid (EDTA), and sulfuric acid. The dose of etripamil to be evaluated in this study is 70 mg with an optional second dose of 70 mg 10 minutes after the first dose if symptoms persist.